Promentis Pharmaceuticals, Inc. is developing novel compounds for the treatment of central nervous system (CNS) disorders including various mental illnesses and addictions. Promentis'
drug development efforts are focused on activating a unique
drug target known to restore glutamatergic neurotransmission and imbalances in oxidative stress. Given the very high level
of unmet medical need, coupled with the fact that there are limited efficacious and safe medications available for
CNS disorders, Promentis is excited to quickly
advance through clinical trials with a keen
focus on making a meaningful impact in
the lives of patients and their families.